Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04504318 · ClinicalTrials.gov registry record · Phase 1
Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
NCT04504318: Completed Phase 1 study, sponsored by Stanford University.
NCT04504318 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 82 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04504318, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
Study Summary
Subcutaneous enoxaparin is currently the gold standard for VTE chemoprophylaxis. However, the efficacy of chemoprophylaxis with subcutaneous enoxaparin is affected by patient-level factors, thus, resulting in VTE events despite guideline-compliant prophylaxis. A population at particular risk is the growing number of patients who undergo autologous breast reconstruction. Direct oral anticoagulants (DOAC) might be a less invasive, yet, more efficacious mode of chemoprophylaxis in this patient population. Hence, the proposed work has the potential to cause a paradigm shift in chemoprophylaxis guidelines in a large population of patients undergoing plastic surgery.
Interventions
- DRUG Apixaban 2.5 MG Oral Tablet
- DRUG Enoxaparin 40Mg/0.4mL Prefilled Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2020-08-12 |
| Est. Completion | 2024-06-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04504318
The ClinicalTrials.gov registry entry for NCT04504318 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apixaban 2.5 MG Oral Tablet is the first listed.
NCT04504318 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04504318 about?
NCT04504318 is a clinical study titled "Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT". Subcutaneous enoxaparin is currently the gold standard for VTE chemoprophylaxis. However, the efficacy of chemoprophylaxis with subcutaneous enoxaparin is affected by patient-level factors, thus, resulting in VTE events despite guideline-compliant prophylaxis. A population at particular risk is the ...
What is the current status of trial NCT04504318?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2020-08-12. Estimated completion is 2024-06-19.
What interventions are being tested in trial NCT04504318?
The interventions under investigation include: Apixaban 2.5 MG Oral Tablet (DRUG), Enoxaparin 40Mg/0.4mL Prefilled Syringe (DRUG).
Who is sponsoring clinical trial NCT04504318?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.